Geneos Wealth Management’s MACOM Technology Solutions MTSI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.71K Buy
+15
New +$4.98K ﹤0.01% 2154
2025
Q3
– Sell
-131
Closed -$18.8K – 2927
2025
Q2
$18.8K Buy
131
+5
+4% +$584 ﹤0.01% 2057
2025
Q1
$12.6K Hold
126
– – ﹤0.01% 2159
2024
Q4
$16.4K Hold
126
– – ﹤0.01% 1821
2024
Q3
$14K Buy
+126
New +$13.2K ﹤0.01% 1700
2021
Q2
– Sell
-112
Closed -$6K – 3019
2021
Q1
$6K Hold
112
– – ﹤0.01% 2604
2020
Q4
$1K Buy
+112
New +$4.78K ﹤0.01% 2810
2017
Q4
– Sell
-27
Closed -$1K – 2199
2017
Q3
$1K Hold
27
– – ﹤0.01% 2060
2017
Q2
$1K Hold
27
– – ﹤0.01% 2013
2017
Q1
$1K Sell
27
-38
-58% -$1.78K ﹤0.01% 2002
2016
Q4
$3K Hold
65
– – ﹤0.01% 1774
2016
Q3
$2K Buy
+65
New +$2.55K ﹤0.01% 1792

Other funds holding MTSI

Geneos Wealth Management's MTSI Position: Q2 2026 in Review

Geneos Wealth Management opened a new position in MACOM Technology Solutions (MTSI) in Q2 2026: 15 shares worth $5.71K. The stake represents ﹤0.01% of the portfolio and ranks #2154 among its holdings. This is a return to the name: Geneos Wealth Management previously reported a position in MTSI as recently as Q2 2025.

Geneos Wealth Management first reported a position in MTSI in Q3 2016 and has held it in 12 quarters since. The position peaked at $18.8K in Q2 2025. 659 funds tracked by Wall St. Rank hold MTSI as of Q2 2026.

  • Geneos Wealth Management held 15 shares of MACOM Technology Solutions worth $5.71K as of Q2 2026.
  • MACOM Technology Solutions was a new Geneos Wealth Management position in Q2 2026.
  • MACOM Technology Solutions made up ﹤0.01% of Geneos Wealth Management's portfolio in Q2 2026, its #2154 holding.
  • Geneos Wealth Management first reported a position in MACOM Technology Solutions in Q3 2016 and has held it in 12 quarters since.
  • Geneos Wealth Management's MACOM Technology Solutions position peaked at $18.8K in Q2 2025.
  • 659 funds tracked by Wall St. Rank held MACOM Technology Solutions as of Q2 2026.

Based on Geneos Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.